Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis

Company Overview

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.75
• Volume: 15,129 shs
• Average Volume: 2,798 shs
• Market Capitalization: $66,350.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACUR Stock Analysis - Frequently Asked Questions

How have ACUR shares performed this year?

Acura Pharmaceuticals' stock was trading at $0.0002 at the beginning of the year. Since then, ACUR stock has increased by 400.0% and is now trading at $0.0010.
View the best growth stocks for 2025 here.

How were Acura Pharmaceuticals' earnings last quarter?

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its quarterly earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.32 million during the quarter.

Does Acura Pharmaceuticals have any subsidiaries?

Acura Pharmaceuticals subsidiaries include these companies: Acura Pharmaceutical Technologies Inc..

How do I buy shares of Acura Pharmaceuticals?

Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acura Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Last Earnings: 2/28/2020
• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ACUR
• Previous Symbol: NASDAQ:ACUR
• CUSIP: 00509L70
• CIK: 786947
• Web: www.acurapharm.com
• Phone: (847) 705-7709
• Fax: 847-705-5399
• Employees: 10
• Year Founded: 1935

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 66,349,000
• Free Float: 52,947,000
• Market Cap: $66,349.00
• Optionable: Not Optionable
• Beta: 2.10